Abstract:In pediatric age and particularly in newborn infants the drug efficacy and safety are influenced by the growth and development on drug Absorption, Distribution, Metabolism and Excretion (ADME). Thanks to the fast development of pharmacogenomics and pharmacogenetics, the drug therapy promises to be adapted to the genetic profile of the individual, reducing considerably the side effects of drugs and increasing their efficacy. Interindividual variability in drug response is well known in both adults and children. Such a variability is multifactorial considering both intrinsic and extrinsic factors. Drug distribution in the neonate is influenced by a variety of age-dependent factors as a total body water content and distribution variations, role of drug transporters, blood/tissue protein binding, blood and tissue pH and perfusion. The development of enzymes involved in human metabolism were classified in 3 categories: 1) those expressed during the whole or part of the fetal period, but silenced or expressed at low levels within 1-2 years after birth; 2) those expressed at relatively constant levels throughout fetal development, but increased to some extent postnatally; and 3) those whose onset of expression can occur in the third trimester, but substantial increase is noted in the first 1-2 years after birth. Besides this intrinsic aspects influencing pharmacokinetics during the neonatal period there are other important events such as inborn or acquired diseases, environment and finally pharmacogenetics and pharmacogenomics. Thousands of deaths every years are caused by fatal drug reactions; among the potential causes there are not only the severity of the disease being treated, drug interactions, nutritional status, renal and liver functions, but also the inherited differences in drug metabolism and genetic polymorphism. Adverse drug reactions (ADRs) among pediatric patients have been shown to be three times more frequent than in adults. On August 2010 The National Institute of Child Health and Human Development (NICHD) addressed patient safety issues in the NICU, recognizing that to understand and prevent adverse events, systematic research and education in safety issues needed. From all these concepts in terms of ADME, pharmacogenetics (relative to a single gene) and pharmacogenomics (relative to many genes) it is becoming more evident the perspective of the new concept of individualized medicine. The goal of this should be to identify which group of patients responds positively, which patients are nonresponders and who experiences adverse reaction for the same drug and dose. The interindividual variability in response to any drug is mostly dependent on DNA sequence variations across the human genome, the haplotype map (HAPMAP). At present there is still a big distance beween the knowledge in genetic and the practical application to model the drug profile to the genetic/genomic profile of the single patient. In the neonatal period the effects of growth in the pharmacodynamic, processes can help optimizing the dosage of neonatal frequently used medicines, thereby, minimizing their toxicity and increasing their efficacy. It should be useful to create accurate dosage adjustments according to the week of development.

Pharmacogenomics and pediatric drug development: science and political power. A narrative review

Pharmacogenomics and Individualized Medication

Pharmacogenomics Clinical Decision Support System:A Review

Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives

Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications

Retrospective Review of Pharmacogenetic Testing at an Academic Children’s Hospital

Study of Pharmacogenomic Information in FDA-approved Drug Labeling to Facilitate Application of Precision Medicine

Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting

[Personalized Dosing from Perspective of Pharmacogenomics of Drug Metabolizing Enzymes and Transporters].

The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review

A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical Resources

Ontogeny and drug metabolism in newborns

Evaluation of Clinical Impact of Pharmacogenomics Knowledge Involved in CPIC Guidelines on Chinese Pediatric Patients

Gene-based drug therapy for children and youth treated with psychoactive medications

Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions

The Pharmacogenetic Journey in Child and Adolescent Psychopharmacology: Are We There Yet?

Pharmacogenomics: A Genetic Approach to Drug Development and Therapy

Progress of Pharmacogenomics and Individual Drug Design

Developmental Changes in Pharmacokinetics and Pharmacodynamics

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation